Palonosetron Hydrochloride– Anti-emesis After Chemotherapy Or Radiotherapy, CAS No.: 135729-62-3

Palonosetron Hydrochloride is a medication used to prevent nausea and vomiting caused by chemotherapy or radiotherapy in cancer patients. It is a highly effective anti-emetic agent that works by blocking a specific neurotransmitter in the brain responsible for triggering nausea and vomiting. As a manufacturer located in China, we are proud to offer this breakthrough medication to our clients located outside of China.

The chemical name of Palonosetron Hydrochloride is (3aS)-2-[(S)-1-[(S)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1-oxopentan-2-yl]-3a,4,5,6-tetrahydro-3H-isoquinoline-1-carboxylic acid hydrochloride. It has a molecular formula of C19H24N4O2.HCl and a molecular weight of 401.88 g/mol.

Palonosetron Hydrochloride is a highly selective serotonin 5-HT3 receptor antagonist, which means it targets only the serotonin 5-HT3 receptor and does not affect other neurotransmitters in the brain. This makes it highly effective in treating nausea and vomiting caused by chemotherapy and radiotherapy, with minimal side effects.

Our product is manufactured using the highest quality raw materials and state-of-the-art manufacturing processes to ensure purity, potency, and consistency. It is available in multiple dosage forms, including tablets, capsules, and injectable solutions, to suit the individual needs of our clients.

Clinical studies have shown that Palonosetron Hydrochloride is highly effective in preventing nausea and vomiting caused by chemotherapy and radiotherapy. It has a longer half-life and a higher binding affinity to the 5-HT3 receptor compared to other anti-emetic agents, which makes it more effective in preventing delayed onset of nausea and vomiting.

Palonosetron Hydrochloride has been approved by the U.S. Food and Drug Administration (FDA) for use in adults and children over six months old. It has also been approved by regulatory agencies in Europe, Japan, and other countries.

As a manufacturer, we pride ourselves on our commitment to quality and customer satisfaction. We offer competitive pricing, fast and reliable shipping, and excellent customer service to ensure that our clients receive the highest quality products and support.

In conclusion, Palonosetron Hydrochloride is a highly effective medication for preventing nausea and vomiting caused by chemotherapy or radiotherapy in cancer patients. It is manufactured to the highest quality standards and is available in multiple dosage forms to suit the individual needs of our clients. We are committed to providing our clients with the best products and support, and we look forward to the opportunity to work with you.

[Name]

Generic Name: Palonosetron Hydrochloride injection

The quality and efficacy consistency of generic drugs were evaluated.

The second generation 5-HT3 receptor antagonist, super antagonistic, long - lasting antiemetic.

The only 5-HT3 receptor antagonist FDA-approved for the prevention of delayed chemotherapy-induced nausea and vomiting.

[Indication]

1. To prevent nausea and vomiting which are induced by tumor treatment (Radiotherapy or chemotherapy)

2. To prevent nausea and vomiting after anesthesia and surgery.

3. To prevent postoperative nausea and vomiting within 24 hours after surgery.

Development History

On December 31, 1993, Hangzhou Jiuyuan Gene Engineering Co., Ltd. was registered and established in Hangzhou New High-tech Development Zone.

On October 14, 1996,the company obtained the Trial-production Approval Number and New Drug Certificate of JILIFEN, the first rhG-CSF injection in China, making China become the third country able to manufacture the drug in large volumes following in the U.S and Japan.

In June, 1998, the drug low molecular weight heparin sodium injection (JIPAILIN) was approved for production and marketing by Ministry of Health.

On September 18, 2003,the company achieved a New Drug Certificate and Manufacture Approval of JIJUFEN, a platelet promoting drug (Recombinant Human Interleukin 11).

In July, 2006, the company initiated the production and sales of the 4th product YINUOJIA (Enoxaparin Sodium Injection), indicating the first officially approved enoxaparin was born in China.

The company was awarded as one of the first "National High-Tech Enterprises" in 2008.

On December 19, the 5th product JIOUTING (Palonosetron Hydrochloride API and injection) officially got approval for manufacture.

In 2010, the new product recombinant human bone repair material BMP-2 (GUYOUDAO) was manufactured and launched on market.

In October, 2013,the company reformed marketing system and established a development strategy of "Marketing First, Total Marketing".

In 2018, the company has initiated a major transformation, focusing on both innovative and generic drugs.

In 2020, R&D center moved to Hangzhou Medicine valley. The company's sales exceeded 1 billion yuan.

Company Honor

National New High-tech Enterprise 

Key New High-tech Enterprise of National Torch Plan 

National superior enterprise of intellectual property

Provincial New High-tech Research & Development Center 

Zhejiang  Provincial Enterprise Technology Center

Zhejiang Famous Trademark 

Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute

Why choose us?

• Our factory is ISO certified, ensuring that our products meet strict quality standards.
• The company takes the route of high-end market competition, continues to expand the scope of product marketing, and steadily increases its market share.
• Our products undergo rigorous testing and quality control measures to ensure that they meet the highest standards of safety and effectiveness.
• In product design, we insist on integrating Chinese elements and are committed to showing Chinese culture to the world.
• We are dedicated to providing exceptional customer service, ensuring that our customers always feel supported and valued.
• Efforts to promote the realization of the maximum comprehensive value of economy, society and environment and sustainable development is always our goal.
• Our team of professionals has extensive experience in the pharmaceutical industry, ensuring the highest level of expertise in API manufacturing.
• We are well-established and professionally managed company. Being a leading manufacturer and supplier of Palonosetron Hydrochloride– Anti-emesis After Chemotherapy Or Radiotherapy, CAS No.: 135729-62-3, we cater to various national and international clients for several years. With an effective and modern production capacity, we can fulfilled the varied requirements of clients.
• We are dedicated to transparency and honesty, ensuring that our customers are always informed about our products and services.
• We share management functions, technical knowledge, and expertise, and stay innovative.

Hot Tags: palonosetron hydrochloride– anti-emesis after chemotherapy or radiotherapy, cas no.: 135729-62-3, China palonosetron hydrochloride– anti-emesis after chemotherapy or radiotherapy, cas no.: 135729-62-3 manufacturers, suppliers, factory, Recombinant Diabetes API, rhIL 11, CAS 121181 53 1, Palonosetron Hydrochloride powder, CAS 135729 62 3, Recombinant Human Interleukin 11